People grappling opioids, whether as medicine, after giving up their use, suffer from withdrawal symptoms such fatigue, nausea, pain, and this condition is known as Opioid withdrawal syndrome (OWS). The symptoms of Opioid withdrawal syndrome may vary with the dependence of a person on opioids.
As per the survey by National Survey on Drug Use and Health, around 5.2 million Americans (which is 2.1% of total US population) used prescription opioids non-medically in the past month revealing similar results. Several Pharma companies such as Chiesi Farmaceutici, Aphios Corporation, and US WorldMeds are working to tackle the current unmet need in an opioid withdrawal syndrome.
Some of the emerging therapies for the Opioid withdrawal syndrome treatment include CHF6563 (Chiesi Farmaceutici), APH-1501 (Aphios Corporation), Lofexidine (US WorldMeds), and several others.
For more details visit https://www.delveinsight.com/blog/opioid-withdrawal-syndrome/ or refer to https://www.delveinsight.com/
#opioid #opioidaddiction #healthcare #pharma #biotech #lifescience #medical
#healthcare #pharma #biotech #lifescience #medical